Bioengineering and Bioscience(CEASE PUBLICATION) Vol. 3(1), pp. 6 - 11
DOI: 10.13189/bb.2015.030102
Reprint (PDF) (224Kb)

State of the Development and Viability of Gene Therapy Ventures

Evan Gary ^1,*, Syed Adeel Ahmed ², Shafin Khan, J. D. ^3
1 College of Engineering, University of New Orleans, United States
² College of Engineering Faculty, University of New Orleans, United States
³ New Orleans BioInnovation Center, United States

ABSTRACT

After years of being ignored due to flaws in the delivery methods, technology has advanced enough to make gene therapy an emerging biotechnology. Gene therapy is significant in that it enables treatment of many conditions for which treating the underlying cause was previously not possible. Glybera, made by Dutch company UniQure, is the only approved gene therapy treatment in the United States and Europe. UniQure and many other companies are now doing research into gene therapy with intent to commercialize the technology. This paper examines companies such as UniQure in the early stages of development (pre-IPO or recent IPO). Venture capital funding as well as clinical trial status are also studied. In addition, both the context of gene therapy in biotech and the potential pricing of treatments are examined with the ultimate goal of assessing the state of gene therapy as a new business and assessing the viability of these ventures. This report is focused on the business of gene therapy and is not intended as a detailed technical examination of the available technologies.

KEYWORDS
Gene Therapy, Commercialization, Venture Capital, Funding, Business, Biotechnology

Cite This Paper in IEEE or APA Citation Styles
(a). IEEE Format:
[1] Evan Gary , Syed Adeel Ahmed , Shafin Khan, J. D. , "State of the Development and Viability of Gene Therapy Ventures," Bioengineering and Bioscience(CEASE PUBLICATION), Vol. 3, No. 1, pp. 6 - 11, 2015. DOI: 10.13189/bb.2015.030102.

(b). APA Format:
Evan Gary , Syed Adeel Ahmed , Shafin Khan, J. D. (2015). State of the Development and Viability of Gene Therapy Ventures. Bioengineering and Bioscience(CEASE PUBLICATION), 3(1), 6 - 11. DOI: 10.13189/bb.2015.030102.